These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 11642598)

  • 1. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of CpG DNA as a mucosal vaccine adjuvant.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel strategies using DNA for the induction of mucosal immunity.
    McCluskie MJ; Davis HL
    Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing vaccines with immune stimulatory CpG DNA.
    Krieg AM; Davis HL
    Curr Opin Mol Ther; 2001 Feb; 3(1):15-24. PubMed ID: 11249727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo.
    Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F
    Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of CpG oligodeoxynucleotides as immune adjuvants.
    Klinman DM; Currie D; Gursel I; Verthelyi D
    Immunol Rev; 2004 Jun; 199():201-16. PubMed ID: 15233736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal adjuvants.
    Freytag LC; Clements JD
    Vaccine; 2005 Mar; 23(15):1804-13. PubMed ID: 15734046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
    Encke J; zu Putlitz J; Stremmel W; Wands JR
    Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo.
    Zhang L; Tian X; Zhou F
    Int Immunopharmacol; 2007 Dec; 7(13):1732-40. PubMed ID: 17996683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets.
    Linghua Z; Xingshan T; Fengzhen Z
    Vaccine; 2008 Jan; 26(2):224-33. PubMed ID: 18063448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ; Weeratna RD; Davis HL
    Vaccine; 2001 Mar; 19(17-19):2657-60. PubMed ID: 11257405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
    Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
    Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    FEMS Immunol Med Microbiol; 2002 Feb; 32(3):179-85. PubMed ID: 11934561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.